Key Changes in Finalized Antitrust Merger Guidelines
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
4d ago
After nearly two years of combined efforts from the Federal Trade Commission and the Antitrust Division of the Department of Justice, the agencies jointly issued much-anticipated merger guidelines identifying the procedures and enforcement practices they will apply for evaluating potential mergers. What might these changes mean for hospitals, health systems, and other stakeholders in the health care industry? On this episode, we discuss some of the key changes in the finalized antitrust merger guidelines and what these guidelines mean for the agencies' approach to enforcement. Visit our site f ..read more
Visit website
Health Equity: Behind the Buzzwords
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
4M ago
Under the Biden administration, the Centers for Medicare & Medicaid Services published a health equity framework that drastically changed the playing field for health plans and other risk-bearing entities. In the wake of these changes, how can health plans, accountable care organizations, and other similar stakeholders successfully create and administer social determinants of health interventions as a means to advance health equity? On this episode, Epstein Becker Green attorneys Jackie Selby, Kevin Malone, and Marjorie Scher discuss the recent national focus on health equity, the actionab ..read more
Visit website
Telehealth Post-Public Health Emergency: What to Expect in 2024
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
4M ago
What trends in state laws and regulations have emerged in the post-public health emergency (PHE) era, and how do these changes impact telehealth stakeholders? At the federal level, many telehealth-related flexibilities have been extended through December 31, 2024, whereas, at the state level, there are wide variations in approach. Many states have continued to push the boundaries of existing telehealth policies, yet no two states are exactly alike in their approach to defining and regulating telehealth. On this episode, Epstein Becker Green attorneys Amy Lerman, Audrey Davis, and Avery Schumac ..read more
Visit website
Antitrust Updates: Changes Affecting Merger Review and Enforcement in 2024 and Beyond
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
5M ago
From wholesale revisions of the merger guidelines to significant amendments to the Hart-Scott-Rodino premerger notification forms, the Federal Trade Commission (FTC) and the Department of Justice (DOJ) have proposed significant changes that, if adopted, will have profound effects on merger review and enforcement for the foreseeable future. What might these changes mean for hospitals, health systems, and other stakeholders in the health care industry? On this episode, we dive into the latest developments in health care antitrust law and analyze the FTC’s and DOJ’s views on mergers in health car ..read more
Visit website
Dietary Supplements: Navigating the Regulatory Maze
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
5M ago
The U.S. Food and Drug Administration’s (FDA’s) broad definition of “misbranding” has created some industry confusion, while the Federal Trade Commission’s (FTC’s) updates to its health products compliance guidance have done the same. In light of these recent actions, what challenges are dietary supplement manufacturers now facing? On this episode, Epstein Becker Green attorneys Jack Wenik, Teddy McCormick, Zach Taylor, and Tracey Gonzalez discuss recent updates to the FDA and FTC guidelines as they apply to dietary supplement manufacturers, as well as new developments with respect to misbrand ..read more
Visit website
Direct Access Laboratory Testing: Future FDA Proposed Regulations on LDTs
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
7M ago
Throughout this series, we've talked about the growth of the direct access testing industry and the types of models developed to support the businesses that are using that type of testing. We've covered reimbursement considerations and physician ordering and specimen collection regulations. How does all of this come together to shape the future of the lab testing industry? On the final episode of our four-part series on direct access laboratory testing, Epstein Becker Green attorneys Bob Hearn, James Boiani, and Megan Robertson discuss licensing and operational considerations, as well as where ..read more
Visit website
Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now?
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
9M ago
In July, the Centers for Medicare & Medicaid Services made significant headway in its implementation of the drug pricing provisions of the Inflation Reduction Act (IRA). How can stakeholders respond to, implement, and comply with all these new provisions? On this episode, hear from special guest Sylvia Yu, Vice President and Senior Counsel of Federal Programs at PhRMA. Sylvia and Epstein Becker Green attorneys Connie Wilkinson and Alexis Boaz discuss the recent updates on the quickly moving implementation of the drug pricing provisions under the IRA and the industry's response. V ..read more
Visit website
Post-Dobbs: One Year Later
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
10M ago
The Supreme Court's decision in Dobbs v. Jackson Women's Health Organization one year ago overturned 50 years of legal precedent protecting the constitutional right to abortion in the United States, leaving the question of whether and how to regulate abortion to individual states. What has happened since and what is to come? On this episode, Epstein Becker Green attorneys Amy Dow, Erin Sutton, and Jessika Tuazon examine how the Dobbs decision has impacted the legal landscape for patient access to abortion, discuss the challenges facing the health care industry, and explore ..read more
Visit website
Managing Trade Secrets and Restrictive Covenants in Health Care M&A Deals
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
11M ago
Like the diversity of the industry itself, merger and acquisition (M&A) transactions in health care take many forms, varying in size and complexity. While buyers tend to focus on several things as part of those transactions, securing key employees post-closing is an important but sometimes overlooked issue. What are some important factors to consider when entering a transaction in a human capital-intensive industry like health care? On this special crossover episode of Diagnosing Health Care and Spilling Secrets, Epstein Becker Green attorneys Kate Rigby, Erik Weibust ..read more
Visit website
The Legal Battle Over Mifepristone
Diagnosing Health Care Podcast
by Epstein Becker & Green, P.C.
1y ago
On April 21, 2023, the U.S. Supreme Court ruled to preserve access to the prescription abortion drug mifepristone. However, while the case continues in the U.S. Court of Appeals for the Fifth Circuit, the future of mifepristone—and the U.S. Food and Drug Administration’s authority to approve new drugs—will continue to be debated on appeal. On this episode, Epstein Becker Green attorneys Erin Sutton, Delia Deschaine, and Avery Schumacher analyze the ongoing legal battle over mifepristone and discuss implications for industry stakeholders, including drug manufacturers, distributors, providers, a ..read more
Visit website

Follow Diagnosing Health Care Podcast on FeedSpot

Continue with Google
Continue with Apple
OR